EV-302: Enfortumab Vedotin and Pembrolizumab

home / pivotal-practice-views-with-the-oncology-brothers / ev-302-enfortumab-vedotin-and-pembrolizumab

Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the EV-302 study and the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.